Skip to main content
. 2017 Feb 28;8(13):22003–22013. doi: 10.18632/oncotarget.15781

Figure 5. MiR-519d sensitizes T-47D-CSCs to cisplatin-induced cell death through the miR-519d/MCL-1 axis.

Figure 5

A. Western blot analysis of the expression of MCL-1 in the T-47D, MCF-7 and BKBR3 BCSCs and the corresponding non-CSCs. B. The transfection efficiency of MCL-1 siRNA and MCL-1 vector in the T-47D-CSCs. C. The cell viability of T-47D-CSCs treated with cisplatin (5 μM), RNAs and plasmid. *P<0.05 vs. cisplatin group, #P<0.05 vs. cisplatin+miR-519d group. D. The IC50 of cisplatin in the T-47D-CSCs transfected with RNAs and plasmid. *P<0.05 vs. miR-NC group, #P<0.05 vs. miR-519d group. E. The percentage of the CSC population of T-47D, MCF-7 and SKBR3 cells treated with cisplatin (5 μM), RNAs and plasmid. *P<0.05 vs. cisplatin group, #P<0.05 vs. cisplatin+miR-519d group.